Switzerland: Nieba takes over from Mouritsen as CEO at Engimmune

By
Nick Herbert
-
Lars Nieba, CEO Engimmune

Engimmune Therapeutics, a biotech company developing novel T-cell receptor (TCR)-based therapeutics, has appointed Lars Nieba to the CEO position, replacing co-founder Søren Mouritsen, who is stepping down in a planned transition. Nieba brings more than 25 years of R&D, business and clinical development, venture capital, manufacturing and product strategy in biopharmaceuticals. He previously held positions…

Membership Required

You must be a HMI Subscriber to view this content.

Subscribe Now »

Already have an account?
Previous articlePharmacierge raises £2.4m for expansion
Next articleThe big picture
Nick Herbert
Nick Herbert
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.
Linkedin

RELATED ARTICLESMORE FROM AUTHOR